SettleThis page contains information on Settle for veterinary use.
The information provided typically includes the following:
- Settle Indications
- Warnings and cautions for Settle
- Direction and dosage information for Settle
SettleThis treatment applies to the following species:
MYCOBACTERIUM CELL WALL FRACTION IMMUNOSTIMULANT
For Veterinary Use Only
For intravenous / intrauterine use only
Recommended as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus.
Dosage & Administration: Administer 1.5 mL by intrauterine instillation with a sterile catheter or by intravenous injection into the jugular vein during the early estrus period. Treatment may be repeated at subsequent natural or induced estrus periods.
Intravenous: Administer 1.5 mL of Settle® by intravenous injection into the jugular vein. Use strict aseptic technique.
Intrauterine: Administer 1.5 mL by intrauterine instillation using strict aseptic technique. Dilute 1.5 mL of Settle® in sterile lactated ringers, normal saline, water for injection or semen extender to provide an approximate final volume of 25 - 50 mL. Aseptically administer the diluted solution into the uterus using a sterile catheter.
Precaution: Store at 2° - 7°C. (35° - 45°F). Do not freeze. Mix thoroughly before injecting. Use entire contents when first opened. Contains gentamicin as a preservative. Do not administer within 21 days of slaughter. If anaphylaxis occurs, administer epinephrine. KEEP OUT OF THE REACH OF CHILDREN.
Cortisone reduces the production of interleukin-1 (IL-1). Mares being treated with corticosteroids or ACTH may not respond to Settle® therapy.
Product Description: Settle® is an emulsion of purified mycobacterium cell walls that have been extracted by a process that reduces their toxic and allergic effects. Settle® enhances the innate humoral immune responses by activating macrophages and stimulating the cloning of polymorphonuclear leukocytes (PMN). These activated phagocytic cells stimulate a cytokine cascade that results in the destruction of bacteria, such as Streptococcus zooepidemicus.
Side EffectsMild fever, drowsiness, and decreased appetite may occur for 1 to 2 days following intravenous injection. These are normal responses to the release of IL-1. An elevated body temperature enhances the immune function by stimulating leukocyte activity and thus is not an adverse side effect.
Packaging: Settle® is available in cartons containing 6 x 1.5 mL single-dose vials.
Manufactured by NovaVive USA Inc., 119 Rowe Rd., Athens, Georgia, U.S.A. 30601
U.S. Vet. Lic. No. 289
Protected by one or more of the following patents:
US: 4744984, 5632995, 5759554, 6139844, 6890541
CA: 1293190, 2154689, 2170142, 2284932, 2284937, 2378888
119 ROWE RD., ATHENS, GA, 30601
|Every effort has been made to ensure the accuracy of the Settle information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-11-28